Jubbonti (denosumab-bbdz) is the first FDA-approved interchangeable biosimilar to Prolia, and Sandoz launched it in the United States on June 2, 2025, after settling a patent dispute with Amgen. Because Jubbonti is a physician-administered injection rather than a pharmacy pickup, Medicare pays for it very differently than a Part D pill: coverage runs through Medicare Part B, priced off a quarterly government formula, not a copay card at the pharmacy counter.
CoveredUSA's guide below breaks down exactly what Medicare pays for a standard 60 mg Jubbonti dose in 2026, what you owe under Original Medicare, Medicare Advantage, and Medigap, and how Jubbonti's price compares to brand-name Prolia. For the deductible and coinsurance mechanics behind these numbers, see copay vs coinsurance explained. Check Medicare Advantage plans in your state to compare formularies before your next injection.
Coverage Breakdown
Direct Answer
Yes, Original Medicare Part B covers Jubbonti when your doctor administers it for an FDA-approved use like osteoporosis. After the 2026 Part B deductible of $283, you generally pay 20% coinsurance, about $324 to $339 per injection depending on the quarter. Medigap can bring that to $0. Medicare Advantage plans typically use a flat copay instead, ranging from $0 to $500 per injection.
What Original Medicare Part B Covers for Jubbonti in 2026
Jubbonti falls under Medicare Part B, not Part D, because it is a physician-administered injectable rather than a self-administered pharmacy drug. Providers bill Jubbonti under HCPCS code Q5136 (denosumab-bbdz, 1 mg per unit), and CMS reimburses at the drug's Average Sales Price (ASP) plus 6%. Because Jubbonti is FDA-approved as an interchangeable biosimilar to Prolia, Medicare covers it for the same indications: postmenopausal women with osteoporosis at high fracture risk, men with osteoporosis at high fracture risk, bone loss from hormone-ablation therapy for certain cancers, and glucocorticoid-induced osteoporosis.
Medicare also has a narrower, separate pathway: the home health osteoporosis drug benefit, which can be billed under either Medicare Part A or Part B depending on your home health episode. If you're a woman whose injectable osteoporosis drug is connected to a bone fracture related to postmenopausal osteoporosis, your doctor certifies you cannot self-inject, and no willing or able caregiver is available, Medicare can pay 100% of both the drug and the home health nurse's visit, with no coinsurance. This is a narrow statutory exception; most Jubbonti injections happen in a doctor's office or outpatient clinic under the standard 20% Part B coinsurance rule described above.
Your Jubbonti Cost Breakdown With Medicare (2026)
CMS updates the ASP-based payment rate for Q5136 every calendar quarter in 2026: about $28.23 per mg in Q1, $27.91 per mg in Q2, $27.67 per mg in Q3, and a preliminary $26.99 per mg in Q4. A standard Jubbonti dose for osteoporosis is 60 mg given once every six months, so the Medicare-allowed amount per injection ranges from roughly $1,620 to $1,694 across the year.
Under Original Medicare with no supplemental coverage, you pay the 2026 Part B annual deductible of $283 first (if you haven't already met it with other Part B services), then 20% coinsurance on the Medicare-allowed amount, roughly $324 to $339 per injection. Since Jubbonti is typically dosed twice a year, your total annual coinsurance runs about $648 to $678, on top of the once-a-year $283 deductible.
- Medicare-allowed amount per 60 mg dose (2026): about $1,620 to $1,694
- Your 20% coinsurance per injection: about $324 to $339
- 2026 Part B annual deductible (paid once, if not already met): $283
- Estimated total annual cost with 2 injections and no supplement: about $931 to $961
What Medicare Advantage Plans Add or Change for Jubbonti
Medicare Advantage plans must cover Jubbonti at least as well as Original Medicare Part B, but they can structure your cost-sharing differently. Observed Medicare Advantage copays for Jubbonti range from $0 to $500 per injection depending on the plan and whether the drug is on a preferred or non-preferred tier of the medical benefit. UnitedHealthcare and most Humana Medicare Advantage plans switched their preferred denosumab product from brand-name Prolia to the lower-cost biosimilar Jubbonti effective September 1, 2025, which can affect your prior authorization requirements even if your dose and diagnosis haven't changed.
Before your appointment, call the member services number on your Medicare Advantage card and ask three questions: is Jubbonti on the medical benefit formulary, does it require prior authorization, and what is your exact copay or coinsurance for HCPCS code Q5136. Your plan's annual out-of-pocket maximum, which Original Medicare does not have, also caps your total 2026 spending once you hit that limit.
How Medigap Eliminates Your Jubbonti Coinsurance
Medigap Plan G and Plan N (and the legacy Plan F, closed to new enrollees since 2020) both pay the Part B 20% coinsurance that Original Medicare leaves you owing. Pair either plan with Original Medicare and your out-of-pocket cost for Jubbonti drops to $0 once you've paid the 2026 Part B deductible of $283 for the year. Plan N carries a small copay for some office visits, but denosumab injections billed as a Part B drug are still covered at 100% after the deductible.
Medigap works best when you buy it during your 6-month Medigap open enrollment window, which starts the month you turn 65 and are enrolled in Part B. During that window, insurers cannot deny coverage or charge more because of a preexisting condition like osteoporosis. Apply for Medigap outside that window in most states, and an insurer can medically underwrite your application or exclude preexisting conditions temporarily.
Jubbonti's Cash Price Without Medicare Coverage (2026)
Without any insurance, Jubbonti's list price runs from about $1,604 at wholesale acquisition cost (WAC) to about $1,925 at average wholesale price (AWP) for a single 60 mg dose in 2026, based on the manufacturer's published pricing of roughly $26.74 to $32.08 per mg. Actual self-pay bills often land higher than the list price because a physician's office or hospital outpatient department adds its own administration and facility fees on top, sometimes pushing a single visit above $2,500 in a hospital setting.
If you're not yet on Medicare, an ACA-compliant marketplace plan must count prescription and injectable drugs among its ten essential health benefits, though the specific tier, prior authorization rules, and coinsurance for a Part B-style drug like Jubbonti still vary by insurer. Sandoz also offers a patient assistance program for people who are uninsured or underinsured; ask your prescriber's office to help you apply before your first injection.
Jubbonti vs. Prolia: Why the Biosimilar Costs Less
The FDA approved Jubbonti on March 5, 2024, as an interchangeable biosimilar to Prolia, meaning the agency found it has no clinically meaningful difference from the brand in safety or effectiveness for the same indications. Sandoz launched Jubbonti in the U.S. on June 2, 2025, priced at launch about 14.5% below Prolia's list price and 7% below Xgeva's list price for the companion product Wyost.
On the 2026 Medicare fee schedule, brand-name Prolia (billed under HCPCS J0897) pays around $29.51 per mg, while Jubbonti (Q5136) pays roughly $27 to $28 per mg depending on the quarter, a savings of about $77 to $150 on a typical 60 mg dose. That gap is why many Medicare Advantage plans and pharmacy benefit managers now steer patients toward Jubbonti as their preferred denosumab product rather than Prolia, without changing the drug's clinical effect.
Frequently Asked Questions
Does Original Medicare cover Jubbonti?
Yes. Original Medicare Part B covers Jubbonti (denosumab-bbdz) as a medical-benefit drug billed under HCPCS code Q5136 when a doctor administers it for an FDA-approved indication such as osteoporosis. After the 2026 Part B deductible of $283, you pay 20% coinsurance, about $324 to $339 per injection depending on the quarter's Medicare-allowed amount.
Does Medicare Advantage cover Jubbonti?
Yes. Medicare Advantage plans must cover Jubbonti at least as well as Original Medicare Part B, but many use a flat copay instead of 20% coinsurance, ranging from $0 to $500 per injection depending on the plan's formulary tier. Some plans require prior authorization, so confirm coverage with your plan before scheduling.
What does Jubbonti cost without Medicare or insurance in 2026?
Jubbonti's 2026 list price for a single 60 mg dose runs about $1,604 at wholesale acquisition cost up to about $1,925 at average wholesale price. Real-world self-pay bills often run higher once a physician's office or hospital outpatient department adds administration and facility fees on top of the drug cost.
Does Medigap cover the Jubbonti coinsurance?
Yes. Medigap Plan G and Plan N both pay the Part B 20% coinsurance for Jubbonti, bringing your out-of-pocket cost to $0 once you've met the 2026 Part B deductible of $283. Buying Medigap during your 6-month open enrollment window avoids medical underwriting based on a preexisting condition like osteoporosis.
Is Jubbonti the same as Prolia?
Jubbonti is an FDA-approved interchangeable biosimilar to Prolia, meaning the FDA found no clinically meaningful difference in safety or effectiveness between the two for the same approved uses. Jubbonti is manufactured by Sandoz and is typically priced lower than brand-name Prolia on both the Medicare fee schedule and the cash list price.
How often do you need a Jubbonti injection?
For osteoporosis, the standard Jubbonti dose is 60 mg injected under the skin once every six months, the same schedule as Prolia. Your doctor may adjust timing based on your bone density results and fracture risk, and each dose is billed separately to Medicare under HCPCS code Q5136.
Does Medicare Part D cover Jubbonti?
No, typically not. Jubbonti is a physician-administered injectable covered through the Part B medical benefit, not through a Part D prescription drug plan. The Part D $2,100 out-of-pocket cap for 2026 does not apply to Jubbonti because it never runs through your Part D pharmacy benefit.
What if my doctor's office charges more than the Medicare-approved amount for Jubbonti?
If your provider accepts Medicare assignment, they cannot legally bill you more than the Medicare-allowed amount plus your standard coinsurance. Ask the billing office to confirm they accept assignment before your appointment, and request an Advance Beneficiary Notice if they expect Medicare might deny the claim.
